| |
David L. Bellitt joins Bioreliance
David L. Bellitt has been named Vice President of Global Commercial Operations, Biologics. Mr. Bellitt will be responsible for all global commercialization activities, including sales, marketing and customer service. He will also serve as a member of the Corporate Operating Committee.
Click here to read the
press release.
James Kramer joins Bioreliance
James J. Kramer, Ph.D, joins BioReliance as Vice President of
Operations, U.S. Biologics. In his new position, Dr. Kramer is the US
Biologic Services Value Stream leader for the company and has direct
ownership for Program Management, Quality, GMP-Cell Banking, Clearance
Services, Molecular Biology, Cell Biology Microbiology, Virology,
In-Vivo Studies, Support Services and Facilities.
Click here to read the
press release.
David A. Dodd to Lead BioReliance Corporation
David A. Dodd has joined BioReliance as the Company's President, Chief
Executive Officer and Chairman of the Board, effective December 3, 2007.
From 2000 through 2006, Mr. Dodd served as President and CEO of
Serologicals Corporation, a publicly traded company that was sold to
Millipore Corporation in 2006 for $1.4 billion. Prior to that, from
1995 Mr. Dodd was President and CEO of Solvay Pharmaceuticals, Inc.
Click here to read the press release.
|
|
|
|
|
Our global regulatory-compliant facilities accommodate
a wide range of services including manufacturing services, biologics safety
testing, analytical services, clinical trial support services, viral/TSE
clearance services, toxicology and laboratory animal diagnostics services.
|
All our modern facilities house spacious and
flexible laboratories fully equipped with state-of-the-art apparatus that
is regularly maintained and calibrated in accordance with stringent quality
assurance and regulatory requirements.
We have a state-of-the-art 50,000 sq. ft toxicology facility, a Laboratory Animal Diagnostic Services (LADS) facility
and biologics safety testing facilities for all your testing needs. |
Our 25,000 sq. ft facilities in Stirling accommodate
a wide range of services including analytical services, clinical trial
support services and biologics safety testing. |
Our Glasgow site consists of approximately
45, 000 sq. ft of custom designed facilities. Our 13,000 sq. ft dedicated
cGMP-compliant production facility has been built to satisfy the stringent
demands of the biotechnology industry. In addition, we have facilities
for electron microscopy and facilities for your all your biologics
safety testing needs. |
| |
|
|
Rockville-USA
Stirling-UK
Glasgow-UK